Collegium Pharmaceutical (NASDAQ:COLL) Share Price Breaks Above 50-Day Moving Average – Here’s Why

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $23.37 and traded as high as $24.18. Collegium Pharmaceutical shares last traded at $24.03, with a volume of 656,444 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on COLL. Oppenheimer began coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price target on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Leerink Partners began coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective for the company. Barclays decreased their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, August 19th. Finally, Weiss Ratings downgraded Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Price Performance

The stock’s fifty day moving average is $23.37 and its 200-day moving average is $33.48. The stock has a market capitalization of $782.32 million, a PE ratio of 19.38, a P/E/G ratio of 0.72 and a beta of 0.73. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. Collegium Pharmaceutical’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.68 EPS. As a group, equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.42 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently bought and sold shares of COLL. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Collegium Pharmaceutical in the third quarter worth $36,000. PNC Financial Services Group Inc. increased its position in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares during the period. Assetmark Inc. increased its position in shares of Collegium Pharmaceutical by 9.3% during the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 335 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 15.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,940 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 778 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 20.6% in the first quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock valued at $167,000 after acquiring an additional 861 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.